8-K: Lisata Therapeutics Enters Exclusive License and Collaboration Agreement with Kuva Labs for Certepetide

Lisata Therapeutics has granted Kuva Labs an exclusive worldwide license for the development and commercialization of certepetide, a novel cyclic peptide.

Summary

• Lisata Therapeutics has entered into an exclusive license and collaboration agreement with Kuva Labs, a subsidiary of Mi2 Holdings, for the development and commercialization of certepetide.
• Kuva will be responsible for all research, development, and commercialization costs.
• Lisata will supply certepetide for clinical use and, after regulatory approval, for commercial use.
• The partnership aims to explore the synergistic potential of certepetide with Kuva's NanoMark imaging technology for solid tumors.
• Kuva will pay Lisata an upfront license fee of $1.0 million, payable in four installments within 12 months.
• Kuva will also pay up to $1.5 million in development milestone payments and up to $17.5 million in commercial milestone payments.
• Lisata will receive a 5% royalty on net sales of licensed products, subject to reductions.
• Lisata will also receive a portion of any sublicense consideration received by Kuva.
• The agreement continues until the end of the royalty term on a product-by-product and country-by-country basis.
• Both parties can terminate the agreement for insolvency or material breach, and Kuva can terminate with 60 days' notice.
• If the SBP License Agreement is terminated, Kuva can elect to continue the license by assuming Lisata's obligations to SBP.

Sentiment

Score: 7

Explanation: The agreement is a positive development for Lisata, providing upfront capital and potential future revenue. However, the royalty rate is subject to reductions and the agreement can be terminated, which introduces some uncertainty.

Positives

• Lisata secures a significant partnership with Kuva Labs for the development and commercialization of certepetide.
• Lisata receives an upfront payment of $1.0 million, providing immediate capital.
• Lisata has the potential to earn up to $19 million in milestone payments.
• Lisata will receive ongoing royalties from net sales of licensed products.
• Kuva assumes all research, development, and commercialization costs, reducing Lisata's financial burden.
• The partnership leverages Lisata's certepetide technology with Kuva's NanoMark imaging technology.

Negatives

• The royalty rate of 5% is subject to reductions, which could impact future revenue.
• The agreement can be terminated by Kuva with 60 days' notice, creating some uncertainty.
• The agreement is dependent on the SBP License Agreement, which could be terminated.

Risks

• The success of the partnership depends on the successful development and commercialization of certepetide.
• The agreement could be terminated by either party for insolvency or material breach.
• The royalty rate is subject to reductions, which could impact future revenue.
• The agreement is dependent on the SBP License Agreement, which could be terminated.
• There is a risk that the synergistic potential of certepetide and NanoMark imaging technology may not be fully realized.

Future Outlook

The agreement is expected to explore the synergistic potential of Lisata's certepetide with Kuva's NanoMark imaging technology in solid tumors, with potential for future revenue through milestone payments and royalties.

Management Comments

• The document does not contain any direct quotes from management, but the signing of the agreement indicates a positive outlook on the partnership.

Industry Context

This agreement reflects a trend in the biotechnology industry towards strategic partnerships to leverage complementary technologies and accelerate drug development. It also highlights the growing interest in targeted therapies and imaging technologies for cancer treatment.

Comparison to Industry Standards

• The upfront payment of $1 million is relatively modest for an exclusive worldwide license, suggesting the deal is heavily weighted towards milestone and royalty payments.
• The 5% royalty rate is within the typical range for early-stage biotech licensing agreements, but the potential for reductions could be a point of concern.
• The total potential milestone payments of $19 million are significant, indicating the potential for substantial future revenue if the product is successful.
• Comparable deals in the biotech space often include higher upfront payments, but the specific terms depend on the stage of development and the perceived value of the technology.

Stakeholder Impact

• Shareholders will likely view the agreement positively due to the potential for future revenue and reduced development costs.
• Employees may see this as a positive development for the company's growth and stability.
• Customers may benefit from the development of new cancer treatments.
• Suppliers may see increased demand for certepetide.
• Creditors may view the agreement as a positive sign of the company's financial health.

Next Steps

• Kuva will assume responsibility for research, development, and commercialization of certepetide.
• Lisata will supply certepetide for clinical use.
• Lisata and Kuva will enter into a Commercial Supply Agreement after regulatory approval.
• Kuva will make the upfront payment of $1.0 million in four installments within 12 months.
• Kuva will pursue regulatory milestones to trigger development milestone payments.
• Kuva will pursue commercial milestones to trigger commercial milestone payments.
• The full text of the agreement will be filed as an exhibit to Lisata's Annual Report on Form 10-K for the fiscal year ending December 31, 2024.

Key Dates

Keywords

Certepetide, License Agreement, Collaboration Agreement, Kuva Labs, Lisata Therapeutics, iRGD, NanoMark, Milestone Payments, Royalties, Drug Development, Oncology